ABC Partner and Corporate Member Esperion announced this week that their NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. ABC Access to Care Initiative Chair, Dr. Keith C. Ferdinand, applauds availability to this new drug.

Comment:
“The approval of new cardiovascular therapies will continue, even in these troubled times of a pandemic. This recent addition in our armamentarium for hypercholesteremia is a welcomed development. How quickly patients can experience the clinical benefits of bempedoic acid will be affected by the extent the provider-patient relationship can be maintained or, more likely, re-established. Hopefully, the prior dual barriers for newer therapies of cost and the need for prior authorization can be overcome.”

— Keith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor, Tulane University SOM

PARTNER RELEASE: Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet

Esperion (NASDAQ: ESPR) announced that NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine is now available in U.S. pharmacies. Esperion is committed to respecting the valuable time of healthcare providers in the current environment while also remaining steadfast to the patients awaiting new options to manage their bad cholesterol.